Connection

Sui-Yuan Chang to Humans

This is a "connection" page, showing publications Sui-Yuan Chang has written about Humans.
Connection Strength

0.052
  1. Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses. Sci Rep. 2021 04 22; 11(1):8692.
    View in: PubMed
    Score: 0.008
  2. Cost-effectiveness of detection of intestinal amebiasis by using serology and specific-amebic-antigen assays among persons with or without human immunodeficiency virus infection. J Clin Microbiol. 2008 Sep; 46(9):3077-9.
    View in: PubMed
    Score: 0.003
  3. D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Virus Titer via Enhanced Furin-Mediated Spike Cleavage. mBio. 2021 08 31; 12(4):e0058721.
    View in: PubMed
    Score: 0.002
  4. Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19. J Formos Med Assoc. 2021 Dec; 120(12):2186-2190.
    View in: PubMed
    Score: 0.002
  5. Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2. Antimicrob Agents Chemother. 2021 03 18; 65(4).
    View in: PubMed
    Score: 0.002
  6. A cross-sectional seroprevalence for COVID-19 among healthcare workers in a tertially care hospital in Taiwan. J Formos Med Assoc. 2021 Jul; 120(7):1459-1463.
    View in: PubMed
    Score: 0.002
  7. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing. ACS Nano. 2021 01 26; 15(1):857-872.
    View in: PubMed
    Score: 0.002
  8. Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection. EMBO Mol Med. 2021 01 11; 13(1):e12828.
    View in: PubMed
    Score: 0.002
  9. Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects. Cell Rep. 2020 10 13; 33(2):108254.
    View in: PubMed
    Score: 0.002
  10. Experience of the use of hydroxychloroquine on patients with COVID-19: A perspective on viral load and cytokine kinetics. J Formos Med Assoc. 2021 May; 120(5):1269-1273.
    View in: PubMed
    Score: 0.002
  11. The origin and underlying driving forces of the SARS-CoV-2 outbreak. J Biomed Sci. 2020 Jun 07; 27(1):73.
    View in: PubMed
    Score: 0.002
  12. A case of transient existence of SARS-CoV-2 RNA in the respiratory tract with the absence of anti-SARS-CoV-2 antibody response. Int J Infect Dis. 2020 Jul; 96:464-466.
    View in: PubMed
    Score: 0.002
  13. Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients. J Infect. 2020 08; 81(2):e55-e58.
    View in: PubMed
    Score: 0.002
  14. Prolonged virus shedding even after seroconversion in a patient with COVID-19. J Infect. 2020 08; 81(2):318-356.
    View in: PubMed
    Score: 0.002
  15. The role of phylogenetic analysis in clarifying the infection source of a COVID-19 patient. J Infect. 2020 07; 81(1):147-178.
    View in: PubMed
    Score: 0.002
  16. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients. Int J Antimicrob Agents. 2019 Jul; 54(1):35-42.
    View in: PubMed
    Score: 0.002
  17. Molecular epidemiology of acute HCV infection in HIV-positive patients from Hong Kong, Taipei, Tokyo. Liver Int. 2019 06; 39(6):1044-1051.
    View in: PubMed
    Score: 0.002
  18. Dolutegravir-rilpivirine coformulation. Curr Opin HIV AIDS. 2018 07; 13(4):320-325.
    View in: PubMed
    Score: 0.002
  19. Magnolol-mediated regulation of plasma triglyceride through affecting lipoprotein lipase activity in apolipoprotein A5 knock-in mice. PLoS One. 2018; 13(2):e0192740.
    View in: PubMed
    Score: 0.002
  20. Neutralizing antiinterferon-? autoantibodies causing disseminated Mycobacterium avium complex infection in an HIV-infected patient on successful combination antiretroviral therapy. AIDS. 2017 11 28; 31(18):2557-2559.
    View in: PubMed
    Score: 0.001
  21. Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy. Sci Rep. 2017 11 23; 7(1):16187.
    View in: PubMed
    Score: 0.001
  22. Awareness and willingness towards pre-exposure prophylaxis against HIV infection among individuals seeking voluntary counselling and testing for HIV in Taiwan: a cross-sectional questionnaire survey. BMJ Open. 2017 Oct 16; 7(10):e015142.
    View in: PubMed
    Score: 0.001
  23. Long-term Durability of Responses to 2 or 3 Doses of Hepatitis A Vaccination in Human Immunodeficiency Virus-Positive Adults on Antiretroviral Therapy. J Infect Dis. 2017 02 15; 215(4):606-613.
    View in: PubMed
    Score: 0.001
  24. Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection. PLoS One. 2016; 11(12):e0169228.
    View in: PubMed
    Score: 0.001
  25. Skin rash related to once-daily boosted darunavir-containing antiretroviral therapy in HIV-infected Taiwanese: incidence and associated factor. J Infect Chemother. 2014 Aug; 20(8):465-70.
    View in: PubMed
    Score: 0.001
  26. Entamoeba histolytica infection in men who have sex with men. Lancet Infect Dis. 2012 Sep; 12(9):729-36.
    View in: PubMed
    Score: 0.001
  27. Recent hepatitis C virus infections in HIV-infected patients in Taiwan: incidence and risk factors. J Clin Microbiol. 2012 Mar; 50(3):781-7.
    View in: PubMed
    Score: 0.001
  28. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2007 Nov 01; 45(9):1221-9.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.